Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration

J Psychiatry Neurosci. 2016 Apr;41(3):E56-7. doi: 10.1503/jpn.150206.

Authors

Ric M Procyshyn¹, Jan L Banasch¹, Alasdair M Barr¹, William G Honer¹

Affiliation

¹ From the Department of Psychiatry, University of British Columbia, Vancouver, BC (Procyshyn, Barr, Honer); the British Columbia Mental Health and Addictions Research Institute, Vancouver, BC (Procyshyn, Honer); the Grey Nuns Hospital, Edmonton, AB (Banasch); and the Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC (Barr).

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antipsychotic Agents / administration & dosage*
Antipsychotic Agents / pharmacokinetics
Delayed-Action Preparations / administration & dosage
Delayed-Action Preparations / pharmacokinetics
Hallucinations / drug therapy
Hallucinations / etiology
Humans
Injections, Intramuscular
Male
Paliperidone Palmitate / administration & dosage*
Paliperidone Palmitate / pharmacokinetics
Schizophrenia / drug therapy*

Substances

Antipsychotic Agents
Delayed-Action Preparations
Paliperidone Palmitate